Patient-specific modeling could help clinicians determine whether an individual’s brain aneurysm is at risk of bursting.

According to the researchers, these drugs may effectively prevent dementia in high-risk individuals with mild to moderate type 2 diabetes, and it may now be worthwhile to give them priority in future clinical trials to determine whether they can be repurposed.

Researchers have begun to investigate whether diabetes drugs could potentially help prevent or cure dementia since type 2 diabetes and dementia share several physiological patterns. However, the results have been inconsistent thus far.

The researchers compared the incidence of dementia in older adults with type 2 diabetes who were receiving either sulfonylurea or thiazolidinedione (TZD) with those receiving metformin alone in order to shed further light on this.

A mechanism has been discovered that regulates cellular levels of tau, a protein whose aberrant accumulation is at the root of tauopathies, a class of devastating neurodegenerative diseases.

The finding was discovered in the laboratory of Michel Cayouette, director of cellular neurobiology research at the Montreal Clinical Research Institute (IRCM) and a medical professor at the University of Montreal.

The research, which was recently published in the journal Science Advances, demonstrates how the protein known as ‘numb’ regulates intracellular tau levels, making numb a potential therapeutic agent for tauopathies.

Identification of molecularly defined gut-to-brain and downstream brain circuits participating in nausea and retching induced by enterotoxins and chemotherapeutic drugs in mice suggests that food poisoning and chemotherapy recruit similar circuit modules to initiate defensive responses.